$350.00
30mg Semaglutide / 3.5mg BPC-157 Blend – Lyophilized *MUST BE RECONSTITUTED FOR RESEARCH APPLICATIONS*
This premium, dual-action research formulation pairs the potent incretin mimetic Semaglutide (30mg) with the cytoprotective pentadecapeptide BPC-157 (3.5mg) to study maximized metabolic expenditure, appetite regulation, and gastrointestinal tissue resilience. By concurrently activating central GLP-1 satiety receptors and upregulating epithelial VEGFR2 healing pathways, this precisely standardized 33.5mg combination vial stands as an ultimate investigative tool for tracking accelerated lipid mobilization, delayed gastric emptying, and the structural mitigation of GLP-1-induced gastrointestinal motility stressors in laboratory models.
Supplied as a stable, premium-grade lyophilized powder in a single synergistic combination vial. Restricted strictly to laboratory and in vitro evaluation.
, brings a host of advantages to the table, including accelerated healing, reduced inflammation, and enhanced tissue repair. Derived from gut enzymes, BPC-157 is known to off-set some of the most well known side-effects related to GLP-1S.
Eterna Peptides presents premium-grade Semaglutide (GLP-1) and BPC-157 dual-action lyophilized powder, an elite synergistic research matrix pairing a powerhouse incretin mimetic with a premier regenerative peptide. Combining 30mg of the highly selective GLP-1 receptor agonist Semaglutide with 3.5mg of the cytoprotective compound BPC-157 inside a single precisely standardized vial, this advanced presentation is engineered to study maximized metabolic rate adaptations and appetite attenuation while tracking the mitigation of common gastrointestinal transit stressors in laboratory models.
### Advanced 33.5mg Synergistic Compound Profile
Each carefully calibrated research vial delivers a precise structural distribution of highly purified compounds:
* **Semaglutide (30mg):** A synthetic peptide analogue of native human glucagon-like peptide-1 (GLP-1). Engineered with an amino acid substitution at position 8 and a hydrophobic C18 fatty diacid side chain at position 26, it heavily resists dipeptidyl peptidase-4 (DPP-4) enzymatic cleavage and exhibits extended albumin-binding kinetics.
* **BPC-157 (3.5mg):** Body Protective Compound 157 is a stable, 15-amino-acid pentadecapeptide derived from a human gastric juice protein segment. It acts as a potent systemic cytoprotective agent, widely investigated for accelerating cellular migration, lining repair, and tissue remodeling curves.
### Mechanism of Action
The Semaglutide / BPC-157 matrix targets complementary endocrine, neurological, and structural checkpoints to explore advanced metabolic signaling and mucosal barrier homeostasis:
* **Glucose-Dependent Insulinotropic Firing:** Semaglutide binds with high affinity to GLP-1 receptors on pancreatic beta cells, triggering a cyclic adenosine monophosphate ($cAMP$) signaling cascade. This drives the synthesis and pulsatile secretion of endogenous insulin strictly in response to elevated glucose baselines.
* **Hypothalamic Satiety Axis Alignment:** Semaglutide readily crosses blood-brain barrier boundaries to target GLP-1 receptors within the arcuate nucleus. This central activation upregulates satiety signals to drive a profound down-regulation of behavioral food-seeking motivation, while peripherally decelerating gastric emptying kinetics.
* **Gastrointestinal Cytoprotection & Tight Junction Support:** BPC-157 operates as a profound mucosal stabilizer. In co-exposure research, it is actively monitored for its ability to preserve the integrity of the gastrointestinal epithelial lining, upregulate tight junction proteins (like zonula occludens-1), and counteract the smooth muscle cramping, nausea simulation, or delayed transit discomfort frequently observed during isolated, high-dose GLP-1 receptor saturation protocols.
* **Angiogenesis Modulation via VEGFR2:** BPC-157 triggers the upregulation of Vascular Endothelial Growth Factor Receptor 2 ($VEGFR2$) pathways. This accelerates microvascular endothelial cell migration and capillary branching, ensuring optimal tissue perfusion, collagen cross-linking, and cellular repair profiles within inflamed or stressed laboratory matrices.
### Research Applications
In preclinical and in vitro laboratory models, Semaglutide / BPC-157 30mg / 3.5mg vials are utilized to investigate:
* High-velocity lipid mobilization, visceral fat reduction kinetics, and resting metabolic rate adaptation.
* Central nervous system satiety pathways, arcuate nucleus neurochemistry, and behavioral appetite suppression.
* Intestinal mucosal barrier defense, tight junction preservation, and the mitigation of GLP-1-induced gastrointestinal motility distress.
* Cellular angiogenesis, fibroblast migration metrics, and soft tissue/collagen structural remodeling under simulated metabolic stress.
Our dual-action vials undergo strict laboratory stabilization, vacuum-drying, and high-purity purification guidelines to ensure absolute peptide chain integrity, rapid reconstitution kinetics, and dependable experimental reproducibility.
—
*Disclaimer: This product is sold strictly for laboratory research and development use only. It is not intended for human consumption, diagnostic, or therapeutic purposes.*
